search icon
search icon
Flag Arrow Down
Română
Română
Magyar
Magyar
English
English
Français
Français
Deutsch
Deutsch
Italiano
Italiano
Español
Español
Русский
Русский
日本語
日本語
中国人
中国人

Change Language

arrow down
  • Română
    Română
  • Magyar
    Magyar
  • English
    English
  • Français
    Français
  • Deutsch
    Deutsch
  • Italiano
    Italiano
  • Español
    Español
  • Русский
    Русский
  • 日本語
    日本語
  • 中国人
    中国人
Sections
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
About Us
Contact
Privacy policy
Terms and conditions
Quickly scroll through news digests and see how they are covered in different publications!
  • News
  • Exclusive
    • INSCOP Surveys
    • Podcast
    • EU
    • Diaspora
    • Republic of Moldova
    • Politics
    • Economy
    • Current Affairs
    • International
    • Sport
    • Health
    • Education
    • IT&C knowledge
    • Arts & Lifestyle
    • Opinions
    • Elections 2025
    • Environment
133 new news items in the last 24 hours
  1. Home
  2. Health

The WHO recommends the use of GLP-1 medications, such as Ozempic and Wegovy, for obesity, but emphasizes the need for a healthy diet and exercise. Pharmaceutical companies are urged to reduce prices to expand access to these.

Raluca Ioana Draghici
whatsapp
facebook
linkedin
x
copy-link copy-link
1 December 2025, 17:27
main event image
Health
www.shutterstock.com
google-preference

Always see our news on Google

The World Health Organization (WHO) has recommended the use of GLP-1-based medications, such as Ozempic and Wegovy, in the treatment of obesity, emphasizing that they should be combined with a healthy diet, physical exercise, and medical monitoring. WHO has urged pharmaceutical companies to reduce prices and expand production to make these therapies accessible even in low-income countries. Although these medications are already well established in developed countries, WHO warns that global access remains limited, estimating that by 2030, less than 10% of people who could benefit from them will have access.

The new WHO therapeutic guideline includes a conditional recommendation for the use of GLP-1, considering the limited data on long-term efficacy and safety. WHO suggests differentiated pricing and voluntary licenses to allow other manufacturers to produce these medications. The expiration of patents for semaglutide, the active ingredient in Ozempic and Wegovy, will allow the emergence of generic medications, which could reduce prices. However, logistical challenges and the need to prepare health systems for the distribution of these medications remain significant obstacles.

Sources

sursa imagine
Digi24
OMS cere ca Ozempic și alte medicamente pentru slăbit să fie disponibile în toată lumea și explică modul corect de utilizare
sursa imagine
Politico Europe
Ozempic-style drugs should be available to all, not just the rich, says WHO

Latest News

17:43

A large power outage is affecting several areas in Bucharest, including Henri Coandă International Airport.

17:30

Four members of a football gallery have been arrested, being suspected of having assaulted a Pakistani citizen.

17:26

The Europol Union requests the authorities to invest in safe vehicles for police officers, after a police car caught fire during a pursuit.

17:26

Soprano Ileana Cotrubaș died at the age of 87.

17:25

Innovation in China: Police robots reduce traffic violations by directing traffic

See more news

NEWS ON THE SAME TOPICS

event image
International
The European Medicines Agency has recommended the approval of the Wegovy tablet, a weight loss medication from Novo Nordisk.
event image
Health
France will start partial reimbursement of treatments for obesity from June, thus becoming the first state in the EU to subsidize these medications.
event image
Health
Cats could benefit from weight loss medications. The first tests are already underway.
event image
International
France will start reimbursing weight loss medications from June 15, becoming the first European country to cover these treatments.
event image
EU
The European Commission is investigating Sanofi for the possible disparagement of a rival flu vaccine intended for vulnerable patients.
event image
Health
WHO begins clinical study for an antiviral drug against Ebola
app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview app preview
WHO ozempic obesity treatment pharmaceutical companies

Editor’s Recommendations

main event image
Politics
55 minutes ago

Radu Burnete, after the meeting at Cotroceni: The leaders of the former coalition received a new version of the salary law / When a possible consensus could come

Sources
imagine sursa
imagine sursa
imagine sursa
imagine sursa
imagine sursa
main event image
Current Affairs
1 hour ago

Radu Miruță, clarifications regarding the maritime drone near Neptun Deep

Sources
imagine sursa
imagine sursa
imagine sursa
main event image
Opinions
7 hours ago

Andrei Pleșu: About public speaking

main event image
Exclusive
3 hours ago
Original Content

EXCLUSIVE The top themes in domestic politics in trends, in the last week

app preview
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
app preview
app store badge google play badge
  • News
  • Exclusive
  • INSCOP Surveys
  • Podcast
  • EU
  • Diaspora
  • Republic of Moldova
  • Politics
  • Economy
  • Current Affairs
  • International
  • Sport
  • Health
  • Education
  • IT&C knowledge
  • Arts & Lifestyle
  • Opinions
  • Elections 2025
  • Environment
  • About Us
  • Contact
Privacy policy
Cookies Policy
Terms and conditions
Open source licenses
All rights reserved Strategic Media Team SRL

Technology in partnership with

anpc-sal anpc-sol